Multimorbidity in patients with atrial fibrillation

被引:1
|
作者
Lobeek, Michelle [1 ]
Middeldorp, Melissa E. [1 ]
Van Gelder, Isabelle C. [1 ]
Rienstra, Michiel [1 ]
机构
[1] Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
来源
OPEN HEART | 2024年 / 11卷 / 01期
关键词
Atrial Fibrillation; RISK FACTORS; Pharmacology; RISK-FACTOR; LIFE-STYLE; REDUCTION; DISEASES; BURDEN; IMPACT; CARE;
D O I
10.1136/openhrt-2024-002641
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is an escalating trend in both the incidence and prevalence of atrial fibrillation (AF). AF is linked to numerous other comorbidities, contributing to the emergence of multimorbidity. The sustained rise in multimorbidity and AF prevalences exerts a significant strain on healthcare systems globally. The understanding of the relation between multimorbidity and AF is essential to determine effective healthcare strategies, improve patient outcomes to adequately address the burden of AF. It not only begins with the accurate identification of comorbidities in the setting of AF. There is also the need to understand the pathophysiology of the different comorbidities and their common interactions, and how multimorbidity influences AF perpetuation. To manage the challenges that rise from the increasing incidence and prevalence of both multimorbidity and AF, such as adverse events and hospitalisations, the treatment of comorbidities in AF has already gained importance and will need to be a primary focus in the forthcoming years. There are numerous challenges to overcome in the treatment of multimorbidity in AF, whereby the identification of comorbidities is essential. Integrated care strategies focused on a comprehensive multimorbidity management with an individual-centred approach need to be determined to improve healthcare strategies and reduce the AF-related risk of frailty, cardiovascular diseases and improve patient outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] HEALTHCARE COSTS OF DIRECT ORAL ANTICOAGULANTS AMONG MEDICARE PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION AND MULTIMORBIDITY
    Dhamane, A. D.
    Ferri, M.
    Keshishian, A.
    Russ, C.
    Atreja, N.
    Thomas, R.
    Leung, G.
    Emir, B.
    Yuce, H.
    DiFusco, M.
    VALUE IN HEALTH, 2022, 25 (07) : S415 - S415
  • [22] Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation
    Claxton, J'Neka S.
    Chamberlain, Alanna M.
    Lutsey, Pamela L.
    Chen, Lin Y.
    MacLehose, Richard F.
    Bengtson, Lindsay G. S.
    Alonso, Alvaro
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (10): : E554 - E567
  • [23] Effects of the Atrial Fibrillation Better Care Pathway on Outcomes Among Clinically Complex Chinese Patients With Atrial Fibrillation With Multimorbidity and Polypharmacy: A Report From the ChiOTEAF Registry
    Kotalczyk, Agnieszka
    Guo, Yutao
    Stefil, Maria
    Wang, Yutang
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (07):
  • [24] DIRECT ORAL ANTICOAGULANTS AND WARFARIN: EFFECTIVENESS AND SAFETY OUTCOMES AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH MULTIMORBIDITY
    Dhamane, Amol
    Ferri, Mauricio
    Keshishian, Allison
    Russ, Cristina
    Thomas, Ruth
    Leung, Gary
    Emir, Birol
    Yuce, Huseyin
    Di Fusco, Manuela
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1501 - 1501
  • [25] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Dhamane, Amol D.
    Ferri, Mauricio
    Keshishian, Allison
    Russ, Cristina
    Atreja, Nipun
    Gutierrez, Cynthia
    Emir, Birol
    Yuce, Huseyin
    Di Fusco, Manuela
    ADVANCES IN THERAPY, 2023, 40 (03) : 887 - 902
  • [26] Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
    Amol D. Dhamane
    Mauricio Ferri
    Allison Keshishian
    Cristina Russ
    Nipun Atreja
    Cynthia Gutierrez
    Birol Emir
    Huseyin Yuce
    Manuela Di Fusco
    Advances in Therapy, 2023, 40 : 887 - 902
  • [27] Bleeding risks with frailty and multimorbidity in patients with atrial fibrillation. A nationwide analysis of 1.4 million subjects
    Fauchier, L.
    Bisson, A.
    Bodin, A.
    Herbert, J.
    Clementy, N.
    Pierre, B.
    Angoulvant, D.
    Hanon, O.
    Babuty, D.
    Lip, G.
    EUROPEAN HEART JOURNAL, 2020, 41 : 685 - 685
  • [28] Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey
    Koziel, Monika
    Simovic, Stefan
    Pavlovic, Nikola
    Kocijancic, Aleksandar
    Paparisto, Vilma
    Music, Ljilja
    Trendafilova, Elina
    Dan, Anca Rodica
    Kusljugic, Zumreta
    Dan, Gheorghe-Andrei
    Lip, Gregory Y. H.
    Potpara, Tatjana S.
    ANNALS OF MEDICINE, 2021, 53 (01) : 17 - 25
  • [29] Multimorbidity in atrial fibrillation: A call for integrated patient-centered care
    Boriani, Giuseppe
    Mei, Davide Antonio
    Imberti, Jacopo Francesco
    KARDIOLOGIA POLSKA, 2023, 81 (06) : 560 - 562
  • [30] Cardiovascular and renal multimorbidity increase risk of atrial fibrillation in the PREVEND cohort
    Van Deutekom, Colinda
    Geelhoed, Bastiaan
    Van Munster, Barbara C.
    Bakker, Stephan J. L.
    Gansevoort, Ron T.
    Van Gelder, Isabelle C.
    Rienstra, Michiel
    OPEN HEART, 2023, 10 (02):